粤港澳大湾区“AI+创新药”沙龙圆满举行：擘画产业发展新蓝图，解码赴港上市新机遇

Core Viewpoint - The event "Intelligent Bay Area · Drug Innovation Future" highlighted the integration of AI technology in innovative drug development and the opportunities for biopharmaceutical companies to leverage the Hong Kong capital market for international growth [1][3][10]. Group 1: Industry Development - The Guangdong-Hong Kong-Macao Greater Bay Area is positioned as a core engine for China's scientific innovation and an important window for opening up, driving the deep integration of biomedicine and artificial intelligence [5]. - The event served as a platform to gather industry wisdom and explore new opportunities in the rapidly developing field of "AI + innovative drugs" [5][10]. - The chairman of Weiguang Holdings emphasized the company's role as a comprehensive investment service provider in life sciences, focusing on biomedicine and related fields [5][6]. Group 2: Government and Institutional Support - The event received strong support from various government bodies, including the Shenzhen Development and Reform Commission and the Shenzhen Municipal Financial Office, indicating a robust institutional backing for the biopharmaceutical sector [3][6]. - The biopharmaceutical industry was recognized as a "new pillar industry" at the national level during the 2026 National Two Sessions, alongside other strategic emerging industries [6]. Group 3: AI and Drug Development - AI technology is reshaping the paradigm of drug discovery, making the process more efficient and cost-effective [9]. - Experts shared insights on how AI can enhance drug development efficiency and the overall ecosystem of the biopharmaceutical industry [7][9]. Group 4: Hong Kong Capital Market Opportunities - The Hong Kong Stock Exchange has become a mainstream choice for biopharmaceutical companies seeking to connect with international capital, with 26 biopharmaceutical companies listed in 2025, an increase of 17 from 2024 [9]. - The event featured discussions on the core challenges and solutions for biopharmaceutical companies looking to list in Hong Kong, including the introduction of specific listing rules [9]. Group 5: Future Outlook - The successful hosting of the salon is expected to strengthen collaboration among biopharmaceutical companies in the Greater Bay Area, pushing the industry towards the high end of the global value chain [10]. - Weiguang Holdings plans to continue leveraging its platform advantages to support biopharmaceutical companies in achieving high-quality development [10].